Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study

OBJECTIVE: Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m(2)) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenof...

Descripción completa

Detalles Bibliográficos
Autores principales: Ting, Ru-Dee, Keech, Anthony C., Drury, Paul L., Donoghoe, Mark W., Hedley, John, Jenkins, Alicia J., Davis, Timothy M.E., Lehto, Seppo, Celermajer, David, Simes, R. John, Rajamani, Kushwin, Stanton, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263870/
https://www.ncbi.nlm.nih.gov/pubmed/22210576
http://dx.doi.org/10.2337/dc11-1109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263870/
https://www.ncbi.nlm.nih.gov/pubmed/22210576
http://dx.doi.org/10.2337/dc11-1109

Ejemplares similares